Biotech Values

[DewDiligence]

AKBA -13%—presumably from this in 2Q18 PR:

https://finance.yahoo.com/news/akebia-therapeutics-announces-second-quarter-200500144.html

Completed U.S. enrollment of the Phase 3 INNO2VATE Conversion study, targeting full enrollment of the INNO2VATE program globally by the end of 2018. The company expects top-line results for the program in the fourth quarter of 2019 or the first quarter of 2020, subject to the accrual of major adverse cardiac events (MACE);